A new oral drug called daraxonrasib has nearly doubled the overall survival rates of pancreatic cancer patients in early trials [3].
This development addresses a critical unmet need for effective treatments for one of the most lethal forms of cancer. By targeting the specific gene mutations that drive the disease, the therapy offers a potential survival benefit for patients who previously had limited options [1, 5].
Dr. Thomas Pudlarz, a medical oncologist and head of the pancreatic care pathway at the Gustave-Roussy Institute in Villejuif, France, said the drug is a new generation targeted therapy [1, 2]. The treatment works by blocking the KRAS mutation, which is responsible for driving most pancreatic cancers [1, 3].
"I think this is truly an earth-shattering moment in pancreatic cancer," Pudlarz said [4].
Trial results were presented in April 2026, with reporting appearing in various outlets between April 14 and May 14, 2026 [6, 7]. The data indicates that daraxonrasib nearly doubled survival rates for those in the trial [3].
"This new generation targeted therapy is one of the first improvements in many years for pancreatic cancer," Pudlarz said [2].
The drug is administered orally, making it a more accessible option for patients compared to some traditional intensive therapies. The Gustave-Roussy Institute continues to lead efforts in the Interception program to refine these care pathways [1, 2].
“I think this is truly an earth-shattering moment in pancreatic cancer.”
The success of daraxonrasib represents a shift toward precision medicine in oncology, moving away from broad chemotherapy toward drugs that target specific genetic drivers like KRAS. If these early trial results are replicated in larger cohorts, it could establish a new standard of care for pancreatic cancer, significantly extending life expectancy for a patient population with historically poor prognoses.
